This conference has been withdrawn from the 2020 conference schedule
As you are aware, coronavirus is having a global impact and the World Health Organization and the Centers for Disease Control have instituted recommendations that include social distancing and cancelling conferences and large gatherings. Since safety of our attendees is always GRC's highest priority, the GRC Board of Trustees has decided to withdraw this conference and it will be rescheduled for 2022. This decision was made out of an abundance of caution and to alleviate the concerns of our conference communities that are scheduled to meet in this timeframe.
The primary objective of the Hemostasis GRC/GRS is to advance the understanding of blood coagulation, platelet biology, anticoagulant pathways, and associated diseases. Such advances are critical since, despite past successes, thrombotic diseases are still major contributors to human mortality and morbidity. First organized by hemostasis pioneers Earl W. Davie and Oscar Ratnoff in 1973, the Hemostasis GRC is widely considered as the premier, small-format scientific meeting in the field. The Hemostasis GRC brings together a community of investigators interested in the biology, biochemistry, and genetics of platelets and coagulation proteins; physicians involved in the treatment of bleeding and thrombotic diseases; and scientists from small and large pharmaceutical/biotechnology companies developing new therapeutics and diagnostics for hemostatic disorders. The sustained impact of this long-running conference on the field has been remarkable. A series of spectacular achievements in the area debuted at past GRCs. The small size of the conference, quality of speakers and participants, and informal settings for discussion of new and unpublished findings have provided a profoundly stimulating environment for leaders in the field and young investigators alike.